IPW
EDIT icon

Impact Partnership Wealth’s Editas Medicine EDIT Stock Holding History

Impact Partnership Wealth’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12
Closed -$94 – 905
2023
Q3 		$94 Buy
+12
New +$103 ﹤0.01% 971

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Impact Partnership Wealth's EDIT Position: Q4 2023 in Review

Impact Partnership Wealth sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 12 shares — an estimated $94 sold.

Impact Partnership Wealth first reported a position in EDIT in Q3 2023 and held it in 1 quarter. The position peaked at $94 in Q3 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

  • Impact Partnership Wealth reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
  • Impact Partnership Wealth sold 12 Editas Medicine shares in Q4 2023, an estimated $94.
  • Impact Partnership Wealth first reported a position in Editas Medicine in Q3 2023 and held it in 1 quarter.
  • Impact Partnership Wealth's Editas Medicine position peaked at $94 in Q3 2023.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Impact Partnership Wealth's 13F filing for Q4 2023, filed 14 Feb 2024.